149 related articles for article (PubMed ID: 15529591)
1. Up to date in pharmacological treatment of dilated cardiomyopathy.
Ginghina C; Teodorescu A; Stoian I; Serban M; Ghiorghiu I; Wohlfart K
Rom J Intern Med; 2004; 42(1):3-13. PubMed ID: 15529591
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis and treatment of cardiomyopathy.
Fonarow GC
Adv Intern Med; 2001; 47():1-45. PubMed ID: 11795071
[TBL] [Abstract][Full Text] [Related]
3. Are Angiotensin-converting enzyme inhibitors and beta-blockers ineffective in children with dilated cardiomyopathy and heart failure?
Singh TP; Almond C
J Am Coll Cardiol; 2010 Aug; 56(10):823; author reply 823-4. PubMed ID: 20797500
[No Abstract] [Full Text] [Related]
4. Mitochondrial A3243G mutation with manifestation of acute dilated cardiomyopathy.
Stalder N; Yarol N; Tozzi P; Rotman S; Morris M; Fellmann F; Schwitter J; Hullin R
Circ Heart Fail; 2012 Jan; 5(1):e1-3. PubMed ID: 22253408
[No Abstract] [Full Text] [Related]
5. Direct effects of 3 combinations of enalapril, metoprolol, and spironolactone on cardiac remodeling in dilated cardiomyopathic hamsters.
Laviolle B; Pape D; Turlin B; Bellissant E
J Card Fail; 2006 Dec; 12(9):752-8. PubMed ID: 17174238
[TBL] [Abstract][Full Text] [Related]
6. The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
Porcu M
Ital Heart J; 2002 Jul; 3(7):437-8. PubMed ID: 12189976
[No Abstract] [Full Text] [Related]
7. Dilated cardiomyopathy : clinical profile and treatment.
Khalil A; Chawla K; Chakravarti A
Indian Pediatr; 2000 Nov; 37(11):1242-6. PubMed ID: 11086307
[No Abstract] [Full Text] [Related]
8. [Peculiarities of cardiac failure treatment in diffuse myocarditis and dilated cardiomyopathy].
Gurevich MA; Iankovskaia MO; Gordienko BV; Mravian SR; Grigor'eva NM
Klin Med (Mosk); 1997; 75(1):48-50. PubMed ID: 9082062
[No Abstract] [Full Text] [Related]
9. Understanding the pathophysiology is the key to novel therapies for canine dilated cardiomyopathy.
Elliott J; Marr CM
Vet J; 2001 Nov; 162(3):168-9. PubMed ID: 11681866
[No Abstract] [Full Text] [Related]
10. Potential novel pharmacological therapies for myocardial remodelling.
Landmesser U; Wollert KC; Drexler H
Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
[TBL] [Abstract][Full Text] [Related]
11. Canine idiopathic dilated cardiomyopathy. Part II: pathophysiology and therapy.
Borgarelli M; Tarducci A; Tidholm A; Häggström J
Vet J; 2001 Nov; 162(3):182-95. PubMed ID: 11681869
[TBL] [Abstract][Full Text] [Related]
12. Evolving therapeutic strategies for dystrophinopathies: potential for conflict between cardiac and skeletal needs.
Colan SD
Circulation; 2005 Nov; 112(18):2756-8. PubMed ID: 16267247
[No Abstract] [Full Text] [Related]
13. C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy.
Satoh M; Nakamura M; Akatsu T; Shimoda Y; Segawa I; Hiramori K
Eur J Heart Fail; 2005 Aug; 7(5):748-54. PubMed ID: 16087131
[TBL] [Abstract][Full Text] [Related]
14. Reversible dilated cardiomyopathy in a patient with Cushing's syndrome.
Yong TY; Li JY
Congest Heart Fail; 2010; 16(2):77-9. PubMed ID: 20412474
[No Abstract] [Full Text] [Related]
15. [Drug therapy of dilated cardiomyopathy].
Guazzi MD; Alimento M; Mundo E; Viecca M
Cardiologia; 1985 Oct; 30(10):909-12. PubMed ID: 2878720
[No Abstract] [Full Text] [Related]
16. Impact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy.
Badenhorst D; Norton GR; Sliwa K; Brooksbank R; Essop R; Sareli P; Woodiwiss AJ
Pharmacogenomics J; 2007 Oct; 7(5):339-45. PubMed ID: 17117186
[TBL] [Abstract][Full Text] [Related]
17. [Mitochondrial cardiomyopathy].
Tanaka M
Nihon Rinsho; 2002 Apr; 60 Suppl 4():306-11. PubMed ID: 12013873
[No Abstract] [Full Text] [Related]
18. Current management of pediatric dilated cardiomyopathy.
Silva JN; Canter CE
Curr Opin Cardiol; 2010 Mar; 25(2):80-7. PubMed ID: 20019605
[TBL] [Abstract][Full Text] [Related]
19. The HF epidemic: the need for new treatment strategies.
Carson PE
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S32-4. PubMed ID: 17199218
[TBL] [Abstract][Full Text] [Related]
20. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
